Protagonist Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
Protagonist Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
Protagonist Therapeutics, Inc. PTGX.OQ reported quarterly adjusted earnings of $3.07 per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -62 cents. The mean expectation of fourteen analysts for the quarter was for earnings of $2.44 per share. Wall Street expected results to range from 13 cents to $3.40 per share.
Revenue rose 5,723.6% to $274.41 million from a year ago; analysts expected $238.47 million.
Protagonist Therapeutics, Inc.'s reported EPS for the quarter was $3.07.
The company reported quarterly net income of $220.02 million.
Protagonist Therapeutics, Inc. shares had risen by 1.8% this quarter and gained 64.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 26.9% in the last three months.
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Protagonist Therapeutics, Inc. is $175.50, about 18.3% above its last closing price of $143.37
This summary was machine generated from LSEG data November 5 at 10:41 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2026 | 2.44 | 3.07 | Beat |
Jun. 30 2026 | 2.08 | 2.29 | Beat |
Mar. 31 2026 | -0.53 | 0.05 | Beat |
Dec. 31 2025 | -0.49 | -0.69 | Missed |
Recent news on Protagonist Therapeutics
See all newsProtagonist Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
Protagonist Therapeutics Q3 revenue surges on Takeda payments
Brief: Protagonist Therapeutics Q3 EPS USD 3.07
UK approves J&J's oral psoriasis pill
U.S. RESEARCH ROUNDUP-Adobe, Braveheart Bio, CACI International